CryoPort (CYRX) vs Jade Biosciences (JBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CryoPort (CYRX) has outperformed Jade Biosciences (JBIO) over the past year, gaining 77.0% versus a gain of 52.3%. Over five years, CYRX leads with a -75.3% price change compared with -97.2% for JBIO. Jade Biosciences is the larger company by market cap ($872.9 million vs $849.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYRX | JBIO |
|---|---|---|
| Share price | $16.77 | $13.73 |
| Market cap | $849.13M | $872.87M |
| 1-day change | -3.37% | -0.33% |
| YTD return | +80.73% | -10.76% |
| 1-year return | +77.04% | +52.32% |
| 5-year return | -75.31% | -97.22% |
| EPS (TTM) | $-0.81 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.36 | $28.00 |
| 52-week low | $7.61 | $8.36 |
| Distance from 52-week high | -8.69% | -50.98% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +17.33% | +265.25% |
| Average volume | 632.63K | 888.66K |
| Shares outstanding | 50.65M | 63.60M |
| Employees | 684 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYRX has outperformed JBIO by 24.7 percentage points over the past year.
About CryoPort
CYRX stock →Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 684 employees
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
CYRX vs JBIO FAQ
Which is bigger, CryoPort or Jade Biosciences?
Jade Biosciences (JBIO) is larger, with a market capitalization of $872.87M compared with $849.13M for CryoPort (CYRX).
Which stock has performed better over the past year, CYRX or JBIO?
CYRX returned +77.04% over the past 12 months, compared with +52.32% for JBIO (price return, excluding dividends). Past performance does not predict future results.
Are CryoPort and Jade Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.